Dicerna Pharmaceuticals (DRNA) PT Raised to $42 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dicerna Pharmaceuticals (DRNA) PT Raised to $49 at B.Riley
June 25, 2021 9:01 AM EDTB.Riley analyst Madhu Kumar raised the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $49.00 (from $40.00) while maintaining a Buy rating.
Reiterate Buy, increase PT from $40 to $49, now includes highly de-risked mid-stage candidate, belcisiran.DRNA recently announced Ph. II initiation of... More